Drug Profile
Trastuzumab biosimilar - Bionovis/The Instituto Vital Brazil
Latest Information Update: 09 Oct 2023
Price :
$50
*
At a glance
- Originator Bionovis; The Instituto Vital Brazil
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Breast cancer; Gastric cancer
Most Recent Events
- 09 Oct 2023 Trastuzumab biosimilar is still in clinical development in Gastric-cancer (Late-stage disease) in Brazil (IV) (Bionovis pipeline, October 2023)
- 09 Oct 2023 Trastuzumab biosimilar is still in clinical development in Breast cancer (Early stage disease and Metastatic disease) in Brazil (IV) (Bionovis pipeline, October 2023)
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer(Early-stage disease) in Brazil (IV)